No evidence for activating mutations, translocations or amplifications at 4p16.3 could be obtained in our collective of HCC cases, indicating that deregulated transcription of FGFR3‐IIIb/IIIc combined with ligand‐induced receptor activation may be the primary mode of action.7 The gene discussed is FGFR3; the disease is hepatocellular carcinoma.